| scholarly article | Q13442814 |
| P50 | author | Sanjay Popat | Q54200048 |
| P2093 | author name string | Timothy A Yap | |
| P2860 | cites work | Envisioning the future of early anticancer drug development | Q51819134 |
| Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus | Q53465653 | ||
| Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib | Q54618926 | ||
| Translating cancer research into targeted therapeutics | Q59060386 | ||
| BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models | Q24649935 | ||
| A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours | Q24653999 | ||
| Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer | Q26865779 | ||
| Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker | Q27681964 | ||
| Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial | Q27851712 | ||
| Afatinib for patients with lung adenocarcinoma and epidermal growth factor receptor mutations (LUX-Lung 2): a phase 2 trial | Q27851751 | ||
| Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. | Q27851896 | ||
| Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers | Q27852116 | ||
| Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. | Q27852408 | ||
| Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. | Q27852553 | ||
| AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer | Q27853013 | ||
| Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma | Q27860881 | ||
| Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR | Q29547545 | ||
| Detection of mutations in EGFR in circulating lung-cancer cells | Q29615033 | ||
| Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial | Q29619975 | ||
| Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study | Q29620648 | ||
| Advances in understanding cancer genomes through second-generation sequencing | Q30014827 | ||
| Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations | Q34135471 | ||
| Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial | Q34263959 | ||
| Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay | Q34762839 | ||
| Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer | Q34773458 | ||
| New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer | Q35196345 | ||
| Phase II trial of dasatinib for patients with acquired resistance to treatment with the epidermal growth factor receptor tyrosine kinase inhibitors erlotinib or gefitinib | Q35592279 | ||
| Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling | Q36406541 | ||
| Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway | Q37715457 | ||
| LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both | Q38118503 | ||
| The role of afatinib in the management of non-small cell lung carcinoma | Q38132282 | ||
| Circulating tumor cells: a multifunctional biomarker | Q38211963 | ||
| TheEGFRT790M Mutation in Acquired Resistance to an Irreversible Second-Generation EGFR Inhibitor | Q39415296 | ||
| Dacomitinib, an emerging HER-targeted therapy for non-small cell lung cancer | Q42355259 | ||
| Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer | Q42780600 | ||
| Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors | Q42948964 | ||
| Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer | Q43061055 | ||
| High T790M Detection Rate in TKI-Naive NSCLC with EGFR Sensitive Mutation: Truth or Artifact? | Q47779220 | ||
| Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations | Q48215164 | ||
| Symptom and quality of life benefit of afatinib in advanced non-small-cell lung cancer patients previously treated with erlotinib or gefitinib: results of a randomized phase IIb/III trial (LUX-Lung 1). | Q48315834 | ||
| First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung | Q48476437 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 285-295 | |
| P577 | publication date | 2014-09-19 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Pharmacogenomics and Personalized Medicine | Q15817568 |
| P1476 | title | Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer | |
| P478 | volume | 7 |
| Q28082181 | Afatinib for the treatment of metastatic non-small cell lung cancer |
| Q55429658 | Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? |
| Q35814162 | Circulating Cell-Free Tumour DNA in the Management of Cancer |
| Q38676692 | Clinical Implications of the T790M Mutation in Disease Characteristics and Treatment Response in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small-Cell Lung Cancer (NSCLC). |
| Q92354500 | Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer |
| Q33566948 | Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode |
| Q37592893 | EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. |
| Q39339545 | Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib |
| Q36544565 | Ibrutinib selectively and irreversibly targets EGFR (L858R, Del19) mutant but is moderately resistant to EGFR (T790M) mutant NSCLC Cells |
| Q37688439 | Ibrutinib targets mutant-EGFR kinase with a distinct binding conformation |
| Q55224621 | Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer. |
| Q35807946 | Next-Generation Covalent Irreversible Kinase Inhibitors in NSCLC: Focus on Afatinib |
| Q35558057 | Novel and emerging targeted-based cancer therapy agents and methods |
| Q31070571 | OncDRS: An integrative clinical and genomic data platform for enabling translational research and precision medicine |
| Q42007563 | Precision medicine: hype or hoax? |
| Q37679981 | Role of epidermal growth factor receptor in lung cancer and targeted therapies |
| Q26745776 | Spotlight on afatinib and its potential in the treatment of squamous cell lung cancer: the evidence so far |
| Q35991895 | The development of precision medicine in clinical practice |
| Q48502619 | Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer. |
| Q88682201 | Xenograft tumors derived from malignant pleural effusion of the patients with non-small-cell lung cancer as models to explore drug resistance |
| Q92188628 | Zebrafish Xenograft Model of Human Lung Cancer for Evaluating Osimertinib Resistance |
Search more.